A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
The acquisition is carried out by a selected group of non-institutional chilean investors.
Founded in 1968, Farmacias Ahumada operates as one of the three main pharmaceutical chains in Chile, with almost 300 drugstores. It offers a range of products and services, such as drugs, natural products, nutritional supplements and beauty items and personal care products. The company is based in Santiago.
Walgreens Boots Alliance is an American public multinational holding headquartered in Illinois. It is an integrated healthcare, pharmacy and retail leader, which owns the pharmacy chains Walgreens in the US and Boots in the UK and internationally, as well as the Benavides brand in Mexico.
Oaklins’ team in Chile advised a group of Chilean investors on the acquisition of Farmacias Ahumada.
Contáctese con el equipo de la transacción
Transacciones relacionadas
OBI Group has acquired the OBI and individual DIG stores from Migros
As part of a strategic review, Migros has decided to divest its DIY business, which included several “Do It + Garden” and “OBI” locations. Migros had operated the Swiss OBI stores as a franchisee. In OBI Group Holding, Migros has found the ideal partner to ensure continuity for both its customers and employees.
Ver másAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Ver másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Ver más